Immunovia’s next generation test to be included in large study of pancreatic cysts funded by the U.S. National Institutes of Health
Summary
We welcome the opportunity to validate the accuracy of our test and assess its clinical use in collaboration with top experts at leading U.S. multidisciplinary pancreatic centers. She is also a member of Immunovias Scientific Advisory Board.In this grant, our goal is to validate an effective early detection blood test for pancreatic cancer in patients with cystic tumors of the pancreas, said Simeone. Branch-duct intraductal papillary mucinous neoplasms (IPMN), the most common incidentally discovered PCNs, have a risk of malignancy approaching 15% within 15 years of diagnosis. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 am CET on August 5, 2024.Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.Immunovias shares (IMMNOV) are listed on Nasdaq Stockholm.